Ensysce Biosciences, Inc. Q2 FY2026 earnings call

• Strategic Acquisition Rationale:
  • Incise’s board of directors completed a thorough evaluation of strategic alternatives focused on maximizing shareholder value, and selected the acquisition of SciBioPharma as the highest value-creating opportunity, due to strong synergies between the two companies and compelling clinical data backing SciBioPharma’s lead program.
• Acquisition and Financing Details:
  • The acquisition of SciBioPharma closed on schedule as announced in the August 6 press release.
  • Concurrent with the acquisition, the company arranged total financing of up to $77 million, including: a $21.5 million private placement of Series C non-voting convertible preferred stock to institutional investors, $17.1 million in cash and cash equivalents held by SciBioPharma from a pre-acquisition convertible note financing, and an additional milestone-based tranche of up to $38.6 million upon achievement of a predefined clinical trial milestone. The round was led by Ally Bridge Group with participation from multiple institutional investors.
  • Post-transaction, pro forma cash on hand is expected to fund operations into late 2027; the additional $38.6 million milestone tranche would extend funding through 2028.
• Lead Program (PSY200) Overview:
  • PSY200 is a botanical psilocybin extract developed to treat complex regional pain syndrome (CRPS), a severe, underserved orphan chronic pain condition with no FDA-approved specific therapies.
  • Unlike standard treatments that only blunt pain symptoms, PSY200 is designed as a neuroplastogenic therapy that targets the underlying neurobiology of CRPS, aiming to deliver durable improvements in both pain and patient function.
  • PSY200 has already received US FDA Orphan Drug Designation for CRPS, which provides regulatory advantages including closer FDA engagement, and 7 years of U.S. market exclusivity if approved.
• Existing Pipeline Commitment:
  • The acquisition and financing will not displace progress on Incise’s existing pipeline: the company will continue advancing PF614 and PF614-MFAR, its novel program for opioid safety.
• Leadership Updates:
  • SciBioPharma Founder and CEO James Morrison joined Incise as President and a member of the board of directors; SciBioPharma CMO Professor Richard Langford continues to lead the PSY200 clinical program.

No financial segment performance data or product segment revenue figures (absolute values or revenue contribution percentages) were disclosed in this corporate update call transcript.

• Following the acquisition and financing, the company expects its existing pro forma cash on hand to fund all planned operations into late 2027, which covers execution of the Phase II trial for PSY200 and delivery of its top-line data.
• If the predefined clinical trial milestone for PSY200 is met, the company will receive an additional $38.6 million in financing that would extend operational funding through 2028 to support subsequent registrational development activities.
• The primary near-term focus of the combined company is clinical execution of the PSY200 Phase II trial, with anticipated top-line data readout expected in the second half of the current year.

• All forward-looking statements related to future performance, clinical trial results, and transaction benefits are subject to inherent risks and uncertainties that could cause actual outcomes to differ materially from expectations, with factors impacting results largely outside of the company’s control.
  • The company refers investors to detailed risk factors disclosed in its SEC filings, including its most recent Form 10-K and Form 10-Q, for a full list of identified risks.
• Clinical development of new therapeutics carries inherent risk that PSY200 may fail to meet efficacy, safety, or tolerability endpoints in the ongoing Phase II trial, which would prevent the company from accessing the $38.6 million milestone tranche of financing and advancing the program to registrational development.

Management explicitly stated no questions would be taken during this corporate update call, so no Q&A section was held.